Novo Nordisk reported DKK 140.8 billion in 2021 sales as Wegovy reached the US
Novo Nordisk's 2021 results show the Wegovy maker's size at the start of the GLP-1 boom, but the company-level figures do not show US prices, coverage or supply.
Novo Nordisk reported net sales of DKK 140.8 billion and operating profit of DKK 58.6 billion for 2021, the year Wegovy was approved in the United States, the company's five-year overview shows [1]. The Danish drugmaker ended the year with 48,478 employees and a closing share price of DKK 368 [1].
Sales grew 10.9% as reported and 13.8% at constant exchange rates, the slowest growth rate among the five years shown in the overview [1]. Net profit was DKK 47.8 billion, and basic earnings per share were DKK 10.40 [1]. The gross margin was 83.2% and the operating margin 41.7% [1]. Research and development spending equaled 12.6% of sales [1].
For the year, the company paid DKK 5.20 per share in dividends, or DKK 23.7 billion in total, a payout ratio of 49.6% [1]. It spent DKK 19.4 billion repurchasing its own shares [1]. Free cash flow was DKK 29.3 billion and total assets were DKK 194.5 billion [1].
The overview puts 2021 next to the four years that followed. Net sales reached DKK 309.1 billion in 2025 and operating profit DKK 127.7 billion [1]. The number of patients reached by the company's obesity and diabetes products rose from 34.9 million in 2021 to 45.6 million in 2025 [1]. Headcount peaked at 77,349 in 2024 and then fell to 69,505 in 2025 [1]. The closing share price climbed to DKK 698 in 2023, slipped to DKK 624 in 2024 and fell to DKK 325 in 2025, a 48% drop in that last year [1].
Spending on property, plant and equipment rose from DKK 6.3 billion in 2021 to DKK 60.1 billion in 2025, and purchases of intangible assets went from DKK 1.05 billion to DKK 30.0 billion [1]. The overview does not break out Wegovy revenue, US-only sales, or how much of that spending was aimed at GLP-1 production, and it does not report how many US patients take semaglutide. Those figures have not been disclosed in the overview [1].
Why it matters for patients
The 2021 figures are the starting point for a period in which semaglutide-based medicines grew from a small part of Novo Nordisk's business into a large one. What the overview reports is company-wide: total sales, total patients reached across obesity and diabetes products, and total manufacturing investment [1]. It does not give US prices, insurance coverage or supply availability, so it cannot show whether any individual patient had an easier or harder time getting a prescription filled.
The workforce numbers also cut both ways. Hiring rose steadily through 2024, then total headcount fell by about 10% in 2025, from 77,349 to 69,505 [1]. Company-wide patient totals were roughly flat that year, edging up about 1%, from 45.2 million to 45.6 million [1].
The share price is a separate story from the clinical one. Novo Nordisk stock closed at DKK 368 at the end of 2021 and DKK 325 at the end of 2025, after peaking at DKK 698 in 2023 [1]. Share prices reflect what investors expect from a company; they say nothing about what a drug does or whether a plan covers it.
What happens next
The five-year overview is published with Novo Nordisk's 2025 annual report [1]. It notes that of the DKK 11.70 per share dividend declared for 2025, DKK 3.75 per share was paid in August 2025, with the remaining DKK 7.95 per share subject to approval at the company's annual general meeting in March 2026 [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.